Results 111 to 120 of about 9,643 (207)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj  

Intravitreal Anti-VEGF Injection Transitions Across Bevacizumab, Biosimilar, and Branded Medications: The IRIS Registry Study. [PDF]

J Vitreoretin Dis
Berkowitz ST, Gilbert JB, Ross CJ, Kearney WC, Lorch A, Miller JW, Rossin EJ, Sternberg P, Finn AP.   +8 more
europepmc   +1 more source

Advances in Biosimilars: A Systematic Review of Machine Learning Applications. [PDF]

Pharmaceuticals (Basel)
Duarte V, Bas TG.
europepmc   +1 more source

Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +1 more source

Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. [PDF]

PLoS One
Gootjes C, Zwaginga JJ, Nikolic T, Roep BO.   +3 more
europepmc   +1 more source

Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. [PDF]

Indian J Ophthalmol
Chakraborty D, Sinha TK, Boral S, Das A.
europepmc   +1 more source

Posterior segment inflammation with venous involvement following a switch to a ranibizumab biosimilar (Ximluci®): a case report. [PDF]

Am J Ophthalmol Case Rep
Conte S, Nassisi M, Mainetti C, Seregni L, Viola F.   +4 more
europepmc   +1 more source

Biosimilars [PDF]

Zeitschrift für Rheumatologie, 2015
G.-R. Burmester, U. Müller-Ladner
openaire   +1 more source

Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]

J Manag Care Spec Pharm
Dayer VW, Hansen RN, Roth J, Jofre-Bonet M, Sullivan SD.   +4 more
europepmc   +1 more source

Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco. [PDF]

BMC Cancer
Errihani H, Berrada N, El Bachiri M, Jouhadi H, Kabbaj O, Bourhafour M, Benider A, Khouchani M, Belbaraka G, Acharki A, Samlali R, Upveja KH.   +11 more
europepmc   +1 more source